加拿大HIV合并感染人群中与HCV治疗相关的障碍和促进因素:患者和治疗提供者的看法。

Canadian liver journal Pub Date : 2022-05-09 eCollection Date: 2022-01-01 DOI:10.3138/canlivj-2021-0020
David Ortiz-Paredes, Afia Amoako, David Lessard, Kim Engler, Bertrand Lebouché, Marina B Klein
{"title":"加拿大HIV合并感染人群中与HCV治疗相关的障碍和促进因素:患者和治疗提供者的看法。","authors":"David Ortiz-Paredes,&nbsp;Afia Amoako,&nbsp;David Lessard,&nbsp;Kim Engler,&nbsp;Bertrand Lebouché,&nbsp;Marina B Klein","doi":"10.3138/canlivj-2021-0020","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Direct-acting antiviral (DAA) uptake is challenging across HIV-hepatitis C (HCV) coinfected populations. This study sought to identify barriers and facilitators related to DAA uptake in priority populations in Canada.</p><p><strong>Methods: </strong>This qualitative descriptive study included 11 people living with HIV with a history of HCV and 15 HCV care providers. Participants were part of either nominal groups (n = 4) or individual interviews (n = 6) in which they identified and ranked barriers and facilitators to DAA uptake. Consolidated lists of barriers and facilitators were identified thematically.</p><p><strong>Results: </strong>Patient participants highly ranked the following barriers: competing priorities and needs (ie, social instability and mental health), delays in care, lack of adherence, and polypharmacy. Provider participant top barriers were the following: competing priorities and needs (ie, social chaos), delays in care (eg, systemic barriers, difficulties engaging patients, lack of trained HCV providers), and HCV-related stigma. Patient participants identified having a strong network of health care providers, family, and friends, possessing intrinsic motivation, and DAAs being a simple and tolerable oral treatment as important facilitators. Provider participant top-ranked facilitators were having resources to identify hard-to-reach populations (eg, patient navigation, outreach), holistic care and addiction management, provider HCV education, and a strong network of interprofessional collaboration.</p><p><strong>Conclusion: </strong>The barriers to DAA initiation addressed by patients and providers overlapped, with some nuances. Multidisciplinary care fostering a strong supportive network and intrinsically motivated patients along with HCV education emerged as key facilitators. This study provides insights for developing potential strategies to improve DAA uptake among HIV-HCV coinfected people in Canada.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":" ","pages":"124-143"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236584/pdf/canlivj-2021-0020.pdf","citationCount":"0","resultStr":"{\"title\":\"Barriers and facilitators related to HCV treatment uptake among HIV coinfected populations in Canada: Patient and treatment provider perceptions.\",\"authors\":\"David Ortiz-Paredes,&nbsp;Afia Amoako,&nbsp;David Lessard,&nbsp;Kim Engler,&nbsp;Bertrand Lebouché,&nbsp;Marina B Klein\",\"doi\":\"10.3138/canlivj-2021-0020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Direct-acting antiviral (DAA) uptake is challenging across HIV-hepatitis C (HCV) coinfected populations. This study sought to identify barriers and facilitators related to DAA uptake in priority populations in Canada.</p><p><strong>Methods: </strong>This qualitative descriptive study included 11 people living with HIV with a history of HCV and 15 HCV care providers. Participants were part of either nominal groups (n = 4) or individual interviews (n = 6) in which they identified and ranked barriers and facilitators to DAA uptake. Consolidated lists of barriers and facilitators were identified thematically.</p><p><strong>Results: </strong>Patient participants highly ranked the following barriers: competing priorities and needs (ie, social instability and mental health), delays in care, lack of adherence, and polypharmacy. Provider participant top barriers were the following: competing priorities and needs (ie, social chaos), delays in care (eg, systemic barriers, difficulties engaging patients, lack of trained HCV providers), and HCV-related stigma. Patient participants identified having a strong network of health care providers, family, and friends, possessing intrinsic motivation, and DAAs being a simple and tolerable oral treatment as important facilitators. Provider participant top-ranked facilitators were having resources to identify hard-to-reach populations (eg, patient navigation, outreach), holistic care and addiction management, provider HCV education, and a strong network of interprofessional collaboration.</p><p><strong>Conclusion: </strong>The barriers to DAA initiation addressed by patients and providers overlapped, with some nuances. Multidisciplinary care fostering a strong supportive network and intrinsically motivated patients along with HCV education emerged as key facilitators. This study provides insights for developing potential strategies to improve DAA uptake among HIV-HCV coinfected people in Canada.</p>\",\"PeriodicalId\":9527,\"journal\":{\"name\":\"Canadian liver journal\",\"volume\":\" \",\"pages\":\"124-143\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236584/pdf/canlivj-2021-0020.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian liver journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3138/canlivj-2021-0020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian liver journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3138/canlivj-2021-0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:在hiv - C型肝炎(HCV)合并感染人群中,直接作用抗病毒药物(DAA)的摄取具有挑战性。本研究旨在确定与加拿大重点人群DAA吸收相关的障碍和促进因素。方法:本定性描述性研究包括11名有HCV病史的HIV感染者和15名HCV医护人员。参与者是名义小组(n = 4)或个人访谈(n = 6)的一部分,其中他们确定并排名DAA吸收的障碍和促进因素。按主题确定了障碍和促进因素的综合清单。结果:患者参与者高度评价了以下障碍:竞争优先事项和需求(即社会不稳定和心理健康),护理延误,缺乏依从性和多种药物。提供者参与的主要障碍如下:相互竞争的优先事项和需求(即社会混乱)、护理延误(例如,系统性障碍、难以吸引患者、缺乏训练有素的HCV提供者)以及与HCV相关的污名。患者参与者认为拥有强大的医疗保健提供者、家庭和朋友网络,拥有内在动机,DAAs是一种简单且可耐受的口服治疗,是重要的促进因素。提供者参与者排名靠前的调解人拥有资源来确定难以接触到的人群(例如,患者导航、外展)、整体护理和成瘾管理、提供者丙型肝炎病毒教育以及强大的跨专业合作网络。结论:患者和医疗服务提供者解决的DAA启动障碍重叠,有一些细微差别。多学科护理培养强大的支持网络和内在动机的患者以及HCV教育成为关键的促进因素。本研究为加拿大HIV-HCV合并感染者改善DAA摄取的潜在策略提供了见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Barriers and facilitators related to HCV treatment uptake among HIV coinfected populations in Canada: Patient and treatment provider perceptions.

Barriers and facilitators related to HCV treatment uptake among HIV coinfected populations in Canada: Patient and treatment provider perceptions.

Background: Direct-acting antiviral (DAA) uptake is challenging across HIV-hepatitis C (HCV) coinfected populations. This study sought to identify barriers and facilitators related to DAA uptake in priority populations in Canada.

Methods: This qualitative descriptive study included 11 people living with HIV with a history of HCV and 15 HCV care providers. Participants were part of either nominal groups (n = 4) or individual interviews (n = 6) in which they identified and ranked barriers and facilitators to DAA uptake. Consolidated lists of barriers and facilitators were identified thematically.

Results: Patient participants highly ranked the following barriers: competing priorities and needs (ie, social instability and mental health), delays in care, lack of adherence, and polypharmacy. Provider participant top barriers were the following: competing priorities and needs (ie, social chaos), delays in care (eg, systemic barriers, difficulties engaging patients, lack of trained HCV providers), and HCV-related stigma. Patient participants identified having a strong network of health care providers, family, and friends, possessing intrinsic motivation, and DAAs being a simple and tolerable oral treatment as important facilitators. Provider participant top-ranked facilitators were having resources to identify hard-to-reach populations (eg, patient navigation, outreach), holistic care and addiction management, provider HCV education, and a strong network of interprofessional collaboration.

Conclusion: The barriers to DAA initiation addressed by patients and providers overlapped, with some nuances. Multidisciplinary care fostering a strong supportive network and intrinsically motivated patients along with HCV education emerged as key facilitators. This study provides insights for developing potential strategies to improve DAA uptake among HIV-HCV coinfected people in Canada.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信